KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Shares Outstanding (2016 - 2025)

Emergent BioSolutions' Shares Outstanding history spans 16 years, with the latest figure at $60.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1.67% year-over-year to $60.9 million; the TTM value through Dec 2025 reached $60.9 million, up 1.67%, while the annual FY2025 figure was $60.9 million, 1.67% up from the prior year.
  • Shares Outstanding reached $60.9 million in Q4 2025 per EBS's latest filing, roughly flat from $60.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $60.9 million in Q4 2025 to a low of $54.8 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $57.4 million, with a median of $57.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: surged 4475.0% in 2021, then increased 0.91% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $55.1 million in 2021, then increased by 1.09% to $55.7 million in 2022, then grew by 3.77% to $57.8 million in 2023, then rose by 3.63% to $59.9 million in 2024, then grew by 1.67% to $60.9 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Shares Outstanding are $60.9 million (Q4 2025), $60.6 million (Q3 2025), and $60.4 million (Q2 2025).